MIRA Pharmaceuticals Reports MIRA-55 Demonstrated Significant Pain Relief Comparable to Celebrex in Chronic Inflammatory Pain Study
Key Highlights
- ➤MIRA-55 significantly reduced mechanical and thermal pain hypersensitivity across all tested doses.
- ➤MIRA-55 pain relief matched celecoxib in magnitude, with no statistically significant treatment difference.
- ➤Pain relief persisted through three weeks without observed tolerance during daily dosing.
- ➤MIRA-55 reduced inflammation-associated paw swelling similarly to celecoxib and was well tolerated.
- ➤MIRA plans a MIRA-55 IND submission in the first quarter of 2027, subject to remaining activities.
Expert Statements
Erez Aminov, Chairman and Chief Executive Officer of MIRA Pharmaceuticals
“We are building a differentiated pain therapeutics franchise around two distinct programs addressing major unmet medical needs”
Erez Aminov, Chairman and Chief Executive Officer of MIRA Pharmaceuticals
“With Ketamir-2 advancing toward Phase 2 clinical development for neuropathic pain and MIRA-55 progressing toward an IND for inflammatory pain, we are creating a pipeline of oral therapies targeting distinct but complementary areas of pain.”
Erez Aminov, Chairman and Chief Executive Officer of MIRA Pharmaceuticals
“We believe this strategy positions MIRA to create meaningful value for patients and shareholders as both programs advance through development.”
Itzchak Angel, Ph.D., Chief Scientific Advisor of MIRA Pharmaceuticals
“One of the most encouraging aspects of these findings is the durability of the response”
Itzchak Angel, Ph.D., Chief Scientific Advisor of MIRA Pharmaceuticals
“MIRA-55 demonstrated sustained analgesic activity over repeated low oral daily dosing, without evidence of tolerance, and produced consistent effects in both male and female animals.”
Itzchak Angel, Ph.D., Chief Scientific Advisor of MIRA Pharmaceuticals
“These results extend our earlier acute pain findings into a model of persistent inflammatory pain.”
Itzchak Angel, Ph.D., Chief Scientific Advisor of MIRA Pharmaceuticals
“The relationship between pain relief and reduced swelling also suggests potentially distinct contributions from pain-signaling and inflammatory pathways, which we are continuing to investigate.”
MIAMI, Oct. 22, 2026 (GLOBE NEWSWIRE) -- MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) ("MIRA" or the "Company"), a clinical-stage pharmaceutical company developing novel oral therapies for neurologic, inflammatory and metabolic disorders, today announced positive results from a 21-day preclinical proof-of-concept study evaluating oral MIRA-55 in a validated model of chronic inflammatory pain. The results support the continued advancement of MIRA-55 toward an Investigational New Drug (IND) submission.
The study demonstrated that once-daily oral MIRA-55 significantly reduced both mechanical and thermal pain hypersensitivity (p < 0.001 versus vehicle) as from the lowest dose used. MIRA-55 achieved pain-relieving effects comparable in magnitude to celecoxib (Celebrex®), a widely prescribed medication for pain and inflammation, at the higher doses evaluated.
Get started
Create a free account to read the full story.